Literature DB >> 1412602

Utility of a one-point (3-hour postdose) plasma metabolic ratio as a phenotyping test using metoprolol in two east Asian populations.

D R Sohn1, M Kusaka, S G Shin, I J Jang, K Chiba, T Ishizaki.   

Abstract

We examined the utility of the postdose 3-h plasma metabolic ratio (MR) as a phenotyping method for assessing genetically determined debrisoquine-type oxidation polymorphism after an oral dose of 100 mg of metoprolol tartrate administered to 402 unrelated, healthy, and native East Asian (218 Korean and 184 Japanese) subjects. All of them were phenotyped simultaneously with the reported MR employing urine samples collected during an 8-h postdose period. In the two populations, the distribution histograms and probit plots of log10plasma MRs derived from the metoprolol/alpha-hydroxymetoprolol concentration values indicated a large gap between the extensive and poor metabolizers who were phenotyped by the reported criteria of the 8-h urinary MR. There were statistically significant (p less than 0.001) correlations (rs = 0.688 and 0.810, respectively) between the postdose urinary and plasma MRs in the Korean and Japanese populations. Two poor metabolizers (one each included in the two racial groups) identified according to the 8-h urinary MR gave the greatest plasma MRs (i.e., 549.7 among the Koreans and 150.0 among the Japanese). The results suggest that the one-point, postdose 3-h plasma MR is also useful for the phenotyping purpose of oxidation pharmacogenetic polymorphism of metoprolol, a widely prescribed beta-adrenoceptor blocking drug.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1412602     DOI: 10.1097/00007691-199206000-00002

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  6 in total

1.  Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.

Authors:  S L Bramer; A Suri
Journal:  Clin Pharmacokinet       Date:  1999       Impact factor: 6.447

2.  Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers.

Authors:  Daniel V Neves; Vera L Lanchote; Miguel Moysés Neto; José A Cardeal da Costa; Carolina P Vieira; Eduardo B Coelho
Journal:  Br J Clin Pharmacol       Date:  2016-04-07       Impact factor: 4.335

Review 3.  Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.

Authors:  D Frank; U Jaehde; U Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2007-02-02       Impact factor: 2.953

4.  Influence of gestational diabetes on the stereoselective pharmacokinetics and placental distribution of metoprolol and its metabolites in parturients.

Authors:  Natalícia de Jesus Antunes; Ricardo Carvalho Cavalli; Maria Paula Marques; Elaine Christine Dantas Moisés; Vera Lucia Lanchote
Journal:  Br J Clin Pharmacol       Date:  2015-04       Impact factor: 4.335

5.  The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots.

Authors:  Massimiliano Donzelli; Adrian Derungs; Maria-Giovanna Serratore; Christoph Noppen; Lana Nezic; Stephan Krähenbühl; Manuel Haschke
Journal:  Clin Pharmacokinet       Date:  2014-03       Impact factor: 6.447

6.  Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.

Authors:  João Paulo Bianchi Ximenez; Jurandyr Moreira de Andrade; Maria Paula Marques; Eduardo Barbosa Coelho; Guilherme Suarez-Kurtz; Vera Lucia Lanchote
Journal:  BMC Pharmacol Toxicol       Date:  2019-12-19       Impact factor: 2.483

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.